Bristol-Myers Squibb Company Ce (CELG-RI) Earnings History
Annual and quarterly earnings data from 1989 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 56.8% | 20.0% | -18.5% |
| 2023 | 76.2% | 18.2% | 17.8% |
| 2022 | 78.0% | 19.7% | 13.7% |
| 2021 | 78.6% | 18.4% | 15.1% |
| 2020 | 72.3% | 5.1% | -21.2% |
Download Data
Export CELG-RI earnings history in CSV or JSON format
Free sign-in required to download data
Bristol-Myers Squibb Company Ce (CELG-RI) Earnings Overview
As of March 1, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) reported trailing twelve-month net income of $6.04B, reflecting -2.1% year-over-year growth. The company earned $2.96 per diluted share over the past four quarters, with a net profit margin of -0.2%.
Looking at the long-term picture, CELG-RI's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.61B in fiscal 2009.
Bristol-Myers Squibb Company Ce maintains positive profitability with a gross margin of 0.6%, operating margin of 0.2%, and net margin of -0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including LLY ($18.41B net income, 0.2% margin), JNJ ($25.12B net income, 0.2% margin), AZN ($10.22B net income, 0.2% margin), CELG-RI has room to improve margins relative to the peer group. Compare CELG-RI vs LLY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$8.95B | -211.5% | $9.66B | $-4.41 | -18.5% | 20.0% |
| 2023 | $8.03B | +26.8% | $8.20B | $3.86 | 17.8% | 18.2% |
| 2022 | $6.33B | -9.5% | $9.10B | $2.95 | 13.7% | 19.7% |
| 2021 | $6.99B | +177.6% | $8.54B | $3.12 | 15.1% | 18.4% |
| 2020 | -$9.02B | -362.1% | $2.18B | $-3.98 | -21.2% | 5.1% |
| 2019 | $3.44B | -30.6% | $5.91B | $2.01 | 13.2% | 22.6% |
| 2018 | $4.95B | +391.8% | $5.12B | $3.03 | 21.9% | 22.7% |
| 2017 | $1.01B | -77.4% | $3.45B | $0.61 | 4.8% | 16.6% |
| 2016 | $4.46B | +174.4% | $4.54B | $2.65 | 22.9% | 23.4% |
| 2015 | $1.62B | -19.0% | $1.73B | $0.97 | 9.8% | 10.4% |
See CELG-RI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELG-RI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CELG-RI vs AGIO
See how CELG-RI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CELG-RI growing earnings?
CELG-RI EPS of $2.96 reflects slowing growth at -2.1%, below the 5-year CAGR of N/A. TTM net income is $6.0B. Expansion rate has moderated.
What are CELG-RI's profit margins?
Bristol-Myers Squibb Company Ce net margin is -0.2%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are CELG-RI's earnings?
CELG-RI earnings data spans 1989-2024. The current earnings trend is -2.1% YoY. Historical data enables comparison across business cycles.